BRAFTOVI® and MEKTOVI® were evaluated in the COLUMBUS Phase III randomized trial, where they achieved 14.9 months mPFS and 33.6 months mOS, showing the potential to become an important therapeutic option in patients with advanced BRAF-mutant melanoma.1,2
In the 5-year COLUMBUS update, BRAFTOVI®+MEKTOVI® combination demonstrated continued long-term benefits and a consistent safety profile with previous observations in patients with BRAF-mutant melanoma.3
We have been on the market for
We are present in
We are present in
Taking care, living better
The objective of our cancer research is to improve the treatment of patients suffering from pathologies for which there are significant unmet therapeutic needs, always staying true to the Pierre Fabre's values, and with the objective of contributing to the well-being of individuals.